All In Biotech

Drug Trial Radar · NCT05407324

Dazucorilant in Patients With Amyotrophic Lateral Sclerosis

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Efficacy of CORT113176 (Dazucorilant) in Patients With Amyotrophic Lateral Sclerosis (DAZALS)

Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 279 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

279

Planned (sponsor's estimate)

Start

Nov 15, 2022

Primary completion

Oct 2026

Study completion Nov 2027

Sponsor

Lead sponsor
Corcept TherapeuticsIndustry
Sponsor type
Industry
First posted
Jun 7, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this 2-part study is to assess the safety and efficacy of CORT113176 (dazucorilant) in patients with Amyotrophic Lateral Sclerosis (ALS).

Conditions

  • Amyotrophic Lateral Sclerosis

Interventions

  • Dazucorilant 300 mgDrug

    300 mg of dazucorilant will be administered once daily in 4 capsules of 75 mg dazucorilant/capsule.

  • Dazucorilant 150 mgDrug

    Dazucorilant and placebo will be administered once daily in 4 capsules, 2 capsules with 75 mg dazucorilant/capsule, and 2 capsules of placebo equivalent.

  • PlaceboOther

    Placebo will be administered once daily in capsules of placebo equivalent.

  • DazucorilantDrug

    Dazucorilant will be administered once daily in 75-mg capsules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline to Week 24 in the ALS Functional Rating Scale-Revised (ALSFRS-R) total score.Time frame: Baseline to Week 24
  2. Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), treatment-related AEs, AEs by severity, and deaths due to AEsTime frame: Baseline to Week 24
  3. Incidence of treatment-emergent AEs and SAEsTime frame: Baseline up to Week 12
  4. Incidence of treatment-emergent AEs leading to dose interruptions, dose reductions, and/or discontinuations of study drugTime frame: Baseline up to Week 12

Locations

35 sites in 10 countries. Site status is shown where the registry gives one.

  • 062

    Phoenix, Arizona

  • 278

    San Francisco, California

  • 287

    Neptune City, New Jersey

  • 353

    New York, New York

  • 108

    Leuven, Belgium

  • 425

    Hamilton, Ontario, Canada

  • 273

    Montreal, Quebec, Canada

  • 422

    Bron, France

  • 258

    Lille, France

  • 257

    Limoges, France

  • 261

    Marseille, France

  • 423

    Montpellier, France

  • 259

    Nice, France

  • 262

    Paris, France

  • 256

    Tours, France

  • 255

    Berlin, Germany

  • 270

    Bonn, Germany

  • 268

    Dresden, Germany

  • 260

    Hanover, Germany

  • 265

    Jena, Germany

  • 386

    München, Germany

  • 267

    Rostock, Germany

  • 269

    Ulm, Germany

  • 253

    Dublin, Ireland

  • 264

    Utrecht, Netherlands

  • 283

    Bydgoszcz, Poland

  • 385

    Krakow, Poland

  • 254

    Warsaw, Poland

  • 274

    Warsaw, Poland

  • 302

    Barcelona, Spain

  • 115

    Barcelona, Spain

  • 303

    Madrid, Spain

  • 282

    Málaga, Spain

  • 194

    Valencia, Spain

  • 263

    Stoke-on-Trent, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.